Case Control Study
Copyright ©The Author(s) 2025.
World J Diabetes. Feb 15, 2025; 16(2): 101501
Published online Feb 15, 2025. doi: 10.4239/wjd.v16.i2.101501
Table 1 Characteristics of Insulin autoantibodies cases and controls

IAA-negative (n = 115)
IAA-positive (n = 115)
Total (n = 230)
P value
Age (years)62.13 ± 10.4363.23 ± 9.7262.68 ± 10.070.41
Gender (male), n (%)66 (57.4)65 (56.5)131 (57.0)0.89
BMI (kg/m2)26.00 ± 3.5425.81 ± 3.5725.91 ± 3.550.69
Hypertension, n (%)61 (53.0)63 (54.8)124 (53.9)0.79
Smoking, n (%)25 (21.74)32 (27.83)57 (24.78)0.29
Uric acid (μmol/L)327.06 ± 91.31309.04 ± 111.72318.05 ± 102.210.18
TC (mmol/L)4.27 ± 1.243.99 ± 1.284.13 ± 1.260.10
LDL-C (mmol/L)2.26 ± 0.982.11 ± 1.012.19 ± 1.000.24
HDL-C (mmol/L)1.13 ± 0.351.22 ± 0.491.18 ± 0.430.11
Triglycerides (mmol/L)2.03 ± 1.552.04 ± 2.532.03 ± 2.090.96
Homocysteine (μmol/L)11.10 ± 7.8610.76 ± 7.7710.93 ± 7.800.74
WBC (× 109/L)6.17 ± 1.665.96 ± 1.716.06 ± 1.690.34
ESR (mm/Hr)15.92 ± 16.0418.84 ± 25.3117.38 ± 21.200.29
CRP (mg/L)4.30 ± 13.894.70 ± 22.894.50 ± 18.890.87
PCT (ng/mL)0.03 (0.02-0.04)0.03 (0.02-0.05)0.03 (0.02-0.05)0.28
D-dimer (mg/L)0.21 (0.19-0.33)0.30 (0.19-0.55)0.24 (0.19-0.41)0.008
UACR (mg/g)12.7 (4.5-103.9)20.8 (3.9-285.5)15.8 (4.3-163.0)0.21
eGFR (mL/min/1.73 m2)90.16 ± 16.2787.64 ± 27.2088.90 ± 22.390.39
Diabetes duration (years)13.03 ± 6.7914.88 ± 7.7613.95 ± 7.330.056
Insulin dosage (U/day)32 (24-40)36 (28-44)34 (26-44)0.12
Insulin use duration (years)5 (1-9)5 (2-9)5 (2-9)0.99
Insulin types
Human insulin, n (%)41 (35.7)53 (46.1)94 (40.9)0.10
Insulin analogs, n (%)77 (67.0)65 (56.5)142 (61.7)0.10
Hypoglycemia, n (%)13 (11.3)26 (22.6)39 (17.0)0.02
HbA1c (%)8.63 ± 1.708.90 ± 1.848.77 ± 1.770.24
Fructosamine (%)22.69 ± 6.0823.02 ± 5.8622.86 ± 5.960.68
FPG (mmol/L)8.30 ± 2.847.86 ± 3.208.08 ± 3.020.28
Plasma insulin (μU/mL)9.8 (5.5-17.6)39.1 (12.0- 102.7)16.1 (7.6-48.5)< 0.001
Plasma C-peptide (ng/mL)1.39 (0.89-2.45)1.50 (0.94-2.39)1.46 (0.90-2.40)0.47